Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases
This trial is active, not recruiting.
|Treatment||radium-223 dichloride (xofigo, bay88-8223)|
|Phase||phase 1/phase 2|
|Start date||December 2013|
|End date||June 2015|
|Trial size||44 participants|
|Trial identifier||NCT01934790, 16506, 2013-003046-17|
Eligible subjects must have completed 6 doses of treatment of radium-223 dichloride and experienced no radium-223 dichloride-related SAEs (serious adverse events) or CTCAE (Common Terminology Criteria for Adverse Events) Grade 3 or 4 adverse event during or after the initial course of radium-223 dichloride that led to the discontinuation of treatment. 40 Subjects will be enrolled and will receive up to 6 doses of radium-223 dichloride 50 kBq/kg IV every 4 weeks.
The subject will be evaluated for AEs (adverse events) and laboratory tests at each visit every 4 weeks, prior to receiving radium-223 dichloride.
After the end of treatment visit the subjects will enter the active follow up period. Related AEs and SAEs and Lab tests will be evaluated at each visit every 4 weeks for the first 12 weeks, then every 12 weeks for up to 2 years after the last dose of radium-223 dichloride.
After the 2 years of active follow-up, subjects will enter the long-term follow-up period and will be followed via telephone follow-up at 6-month intervals for late toxicities and survival up to 7 years after the last dose of radium-223 dichloride or until death.
Joint safety reviews will regularly take place to oversee safety of the subjects conducted at regular intervals.
An interim analysis of the safety data will be conducted during the study.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|Los Angeles, CA 90033||not available||no longer recruiting|
|Stanford, CA 94305||not available||no longer recruiting|
|New Orleans, LA 70112||not available||no longer recruiting|
|Omaha, NE 68130||not available||no longer recruiting|
|Syracuse, NY 13210||not available||no longer recruiting|
|Charlotte, NC 28203||not available||no longer recruiting|
|Kuopio, Finland 70210||not available||no longer recruiting|
|Seinäjoki, Finland FIN 60220||not available||no longer recruiting|
|Tampere, Finland 33521||not available||no longer recruiting|
|München, Germany 81675||not available||no longer recruiting|
|Rostock, Germany 18107||not available||no longer recruiting|
|Aachen, Germany 52074||not available||no longer recruiting|
|Dresden, Germany 01307||not available||no longer recruiting|
|Cork, Ireland||not available||no longer recruiting|
|Galway, Ireland||not available||no longer recruiting|
|Haifa, Israel 3109601||not available||no longer recruiting|
|Jerusalem, Israel 9112001||not available||no longer recruiting|
|Kfar Saba, Israel 4428164||not available||no longer recruiting|
|Petah Tikva, Israel 4941492||not available||no longer recruiting|
|Meldola, Italy 47014||not available||no longer recruiting|
|Genova, Italy 16128||not available||no longer recruiting|
|Milano, Italy 20133||not available||no longer recruiting|
|Bergen, Norway 5021||not available||no longer recruiting|
|Lørenskog, Norway 1478||not available||no longer recruiting|
|Ålesund, Norway 6026||not available||no longer recruiting|
|Córdoba, Spain 14004||not available||no longer recruiting|
|Barcelona, Spain 08025||not available||no longer recruiting|
|Málaga, Spain 29010||not available||no longer recruiting|
|Stockholm, Sweden 171 76||not available||no longer recruiting|
|Umeå, Sweden 901 85||not available||no longer recruiting|
|Nottingham, United Kingdom NG5 1PB||not available||no longer recruiting|
|Belfast, United Kingdom BT9 7AB||not available||no longer recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
Number of participants with either treatment-related AEs (adverse events) or SAEs (serious adverse events)
time frame: Up to 7 months
Number of participants with Radium-223 dichloride-related SAEs in the active follow-up period
time frame: Up to 2 years after last treatment
Change in complete blood count
time frame: Up to 2.5 years
Number of participants who discontinue Radium-223 dichloride treatment due to treatment emergent AEs or death
time frame: Up to 7 months
Male participants at least 18 years old.
Inclusion Criteria: - Histologically or cytologically confirmed adenocarcinoma of the prostate at any given point in time during disease history - CRPC (castration-resistant prostate cancer) with clinical or radiologically confirmed bone progression - Treatment with 6 injections of radium-223 dichloride 50 kBq/kg and no evidence of progression to bone (according to Prostate Cancer Clinical Trials Working Group 2 [PCWG2] criteria) during the first course of treatment - Signed written informed consent prior to participating in any study related procedures. Willing and able to comply with the protocol, including follow-up visits and examinations Exclusion Criteria: - History of a radium-223 dichloride-related serious adverse event (SAE) or CTCAE Grade 3 or 4 adverse event (AE) during or after the initial course of radium-223 dichloride treatment that led to the discontinuation of treatment - Less than 30 days from the last dose administered in the initial course of radium-223 dichloride treatment - Visceral metastases 1 cm or greater in largest diameter and / or requiring local or systemic therapeutic intervention, as assessed by abdominal and pelvic magnetic resonance imaging (MRI) / computed tomography (CT) scan and / or chest X-ray within 30 days of the start of treatment - Lymphadenopathy with lymph nodes exceeding 6 cm in short-axis diameter and / or requiring local or systemic therapeutic intervention. Enlarged lymph nodes of any size if the lymphadenopathy is thought to be a contributor to concurrent hydronephrosis. - Current central nervous system (CNS) metastases - Chronic conditions associated with non-malignant abnormal bone growth (e.g., confirmed Paget's disease of bone) - Treatment with chemotherapy after the initial course of radium-223 dichloride treatment - Prior hemibody external radiotherapy - Prior systemic radiotherapy with strontium-89, samarium-153, rhenium-186, or rhenium-188 - Any other serious illness or medical conditions - Crohn's disease or ulcerative colitis - History of documented bone marrow dysplasia - Unmanageable fecal incontinence - Imminent or established spinal cord compression based on clinical findings and / or MRI that has not yet been treated - Other malignancy treated within the last 3 years (except non-melanoma skin cancer or low-grade superficial bladder cancer)
|Official title||A Re-treatment Safety Study of Radium-223 Dichloride in Subjects With Castration-resistant Prostate Cancer With Bone Metastases Who Received an Initial Course of Six Doses of Radium-223 Dichloride 50 kBq/kg Every Four Weeks|
Call for more information